Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection.

Literature DB >> 17143590

Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection.

Francesca Bellisai¹, Chiara Giannitti, Alessandro Donvito, Mauro Galeazzi.

Abstract

We describe two cases of rheumatoid arthritis (RA) patients and concomitant hepatitis C virus infection (HCV), treated with cyclosporine A (CsA) and anti-TNF-alpha agents. SGOT/SGPT and HCV-RNA serum levels remained unchanged longer than 1 year of treatment. No side effects were registered. We suggest that combination therapy with CsA and TNF-alpha blockers should be considered safe and well-tolerated in the treatment of HCV-positive RA patients.

Entities: Chemical

Mesh：

Substances：

Year: 2006 PMID： 17143590 DOI： 10.1007/s10067-006-0412-1

Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 3.650

14 in total

Review 1. Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation.

Authors: T Casanovas Taltavull
Journal: Transplant Proc Date: 2004-03 Impact factor: 1.066

Review 2. Infections and anti-tumor necrosis factor alpha therapy.

Authors: Todd Ellerin; Robert H Rubin; Michael E Weinblatt
Journal: Arthritis Rheum Date: 2003-11

3. Immunosuppression for HCV following liver transplantation: enough is just enough.

Authors: G W McCaughan
Journal: Transplantation Date: 2004-11-27 Impact factor: 4.939

4. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C.

Authors: R Fukuda; N Ishimura; S Ishihara; A Chowdhury; N Morlyama; C Nogami; T Miyake; M Niigaki; A Tokuda; S Satoh; S Sakai; S Akagi; M Watanabe; S Fukumoto
Journal: Liver Date: 1996-12

5. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection.

Authors: B Kallinowski; K Haseroth; G Marinos; C Hanck; W Stremmel; L Theilmann; M V Singer; S Rossol
Journal: Clin Exp Immunol Date: 1998-02 Impact factor: 4.330

6. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins.

Authors: Mina Nakagawa; Naoya Sakamoto; Yoko Tanabe; Tomoyuki Koyama; Yasuhiro Itsui; Yoshie Takeda; Cheng-Hsin Chen; Sei Kakinuma; Shinya Oooka; Shinya Maekawa; Nobuyuki Enomoto; Mamoru Watanabe
Journal: Gastroenterology Date: 2005-09 Impact factor: 22.682

7. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection.

Authors: D R Nelson; H L Lim; C G Marousis; J W Fang; G L Davis; L Shen; M S Urdea; J A Kolberg; J Y Lau
Journal: Dig Dis Sci Date: 1997-12 Impact factor: 3.199

8. Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells.

Authors: M Nakamuta; M Kohjima; M Fukushima; S Morizono; K Kotoh; N Kobayashi; M Enjoji
Journal: Transplant Proc Date: 2005-12 Impact factor: 1.066

9. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

Authors: Koichi Watashi; Makoto Hijikata; Masahiro Hosaka; Masashi Yamaji; Kunitada Shimotohno
Journal: Hepatology Date: 2003-11 Impact factor: 17.425

10. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.

Authors: J R Peterson; F C Hsu; P A Simkin; M H Wener
Journal: Ann Rheum Dis Date: 2003-11 Impact factor: 19.103

8 in total

Review 1. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Authors: M Afshar; A D Martinez; R L Gallo; T R Hata
Journal: J Eur Acad Dermatol Venereol Date: 2012-06-01 Impact factor: 6.166

Review 2. Update on the natural history and systemic treatment of psoriasis.

Authors: Stephen K Richardson; Joel M Gelfand
Journal: Adv Dermatol Date: 2008

3. A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis.

Authors: Eun Ju Lee; Min Kyung Shin; Nack In Kim
Journal: Ann Dermatol Date: 2010-05-17 Impact factor: 1.444